-
Menopausal hormone therapy and risk of VTE and AD; patients' understanding of chemotherapy benefits; and FDA actions.
-
In the JUPITER primary prevention trial, the cardiovascular and mortality benefits of statin therapy exceeded the diabetes hazard, including patients at high risk of developing diabetes.
-
The authors conducted a literature review of Medline and the Cochrane database to identify studies comparing outcomes in Bells palsy patients who received steroid/antiviral agents vs no medication. Patients with new onset Bells palsy treated with steroids displayed significantly better improvement in facial function compared with patients not taking this medication.
-
Dabigatran has been demonstrated to decrease the rate of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF) by one-third, while also decreasing the rate of intracranial bleeding by two-thirds compared with warfarin.
-
-
The role of omega-3 fatty acids in prostate cancer risk has been inconsistent and it has been difficult to draw practical and clinically useful conclusions from the research.
-
-
Svanström and colleagues in copenhagen examined the risk of cardiovascular deaths in association with azithromycin use in a nationwide historical cohort study of Danish adults aged 18-64 years.
-
A highly selective alpha-2 adrenergic receptor agonist has been approved by the FDA for the treatment of persistent facial erythema of rosacea in adults.
-
Evidence-based updates in primary care medicine By Louis Kuritzky, MD
Supplement to Clinical Cardiology Alert, Clinical Oncology Alert, Critical Care Alert, Hospital Medicine Alert, Infectious Disease Alert, Neurology Alert, OB/GYN Clinical Alert, Primary Care Reports.
